Synairgen plc
Price information
Instrument information
Last 5 trades
| Date | Time | Price | Currency | Volume | Trade Value | Trade type | Trade flag | MIC |
|---|---|---|---|---|---|---|---|---|
| 30.10.20 | 18:03:11 | 168.00 | GBX | 411 | 690.48 | Off-Book | TNCP | XOFF |
| 30.10.20 | 17:29:35 | 170.79 | GBX | 77,000 | 131,510.61 | Off-Book | TNCP | XOFF |
| 30.10.20 | 16:28:11 | 167.70 | GBX | 4,768 | 7,995.94 | Off-Book | LRGS | AIMX |
| 30.10.20 | 15:20:01 | 166.00 | GBX | 12,043 | 19,991.38 | Off-Book | LRGS | AIMX |
| 30.10.20 | 15:17:19 | 166.00 | GBX | 9,031 | 14,991.46 | Off-Book | LRGS | AIMX |
Equity Research
from Synairgen plc
Synairgen - £80m funding for COVID-19 study and supply chain
Synairgen has raised £80m to fund a Phase III trial for SNG001 in COVID-19 disease, which is due to commence in Q4 2020 and will be run globally by Parexel, with results expected in Q2 2021, and scale up manufacturing. This follows a successful pre-IND meeting with the FDA, which provided the guidan ...
View report
Morning Note – 29 September 2020
Chariot Oil & Gas (CHAR): Corp | dotDigital (DOTD): Corp | Gateley (GTLY): Corp | Iofina (IOF): Corp | Synairgen (SNG): Corp | Universe Group (UNG): Corp
View report
Synairgen - Interims and fuller Phase II data analysis
Synairgen reported interim results to 30 June in which the adjusted net loss was £3.9m with period-end cash of £10.9m. A fuller analysis and disclosure of the Phase II trial of inhaled interferon (SNG001) in hospitalised COVID-19 patients confirms the earlier optimism we had at the ti ...
View report
SP Angel Healthcare Conditions
Synairgen (SNG.L): Positive interim data from trial of SNG001 in COPD patients | Silence Therapeutics (SLN.L): R&D Update | Verona Pharma plc (AIM: VRP.L): Initation of pilot study in COVID-19 patients
View reportMorning Note – 8 September 2020
Alumasc (ALU): Corp | Bigblu Broadband (BBB): Corp | Flowtech Fluidpower (FLO): Corp | STM (STM): Corp | Synairgen (SNG): Corp
View report